SCHEMBL14770546

SCHEMBL14770546

CCOc1ccc2[nH]c(C(C)c3ccc(OCc4cc(F)ccc4F)cc3C)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1C Q13936 1/20 0.45
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
HRH4 Q9H3N8 1/20 0.32
HTR2C P28335 3/20 0.32
SLC6A4 P31645 3/20 0.32
HTR2A P28223 2/20 0.32
MAOB P27338 2/20 0.32
CYP1A1 P04798 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP1B1 Q16678 1/20 0.32
POLB P06746 1/20 0.32
FPR1 P21462 1/20 0.31
HPGD P15428 3/20 0.31
MAPT P10636 3/20 0.31
HSD17B10 Q99714 3/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
KDM4E B2RXH2 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770526 0.89 CACNA1C (0.48) CACNA1CMEN1HTTKMT2AHTR2C
SCHEMBL12065289 0.83 CACNA1C (0.46) CACNA1CMEN1HTTKMT2AHTR2C
SCHEMBL12065620 0.82 CACNA1C (0.48) CACNA1CMEN1HTTKMT2AHTR2C
SCHEMBL14770545 0.82 CACNA1C (0.44) CACNA1CMEN1HTTKMT2APOLB
SCHEMBL14770547 0.81 CACNA1C (0.43) CACNA1CMEN1HTTKMT2ASLC6A4
SCHEMBL12065600 0.81 CACNA1C (0.47) CACNA1CMEN1HTTKMT2AHTR2C
SCHEMBL14774018 0.81 CACNA1C (0.47) CACNA1CMEN1HTTKMT2AHTR2C
SCHEMBL14770531 0.81 CACNA1C (0.40) CACNA1CMEN1HTTKMT2AHTR2C
SCHEMBL14770598 0.81 KMT2A (0.43) CACNA1CMEN1HTTKMT2AHTR2A
SCHEMBL12065310 0.81 CACNA1C (0.45) CACNA1CMEN1HTTKMT2ACYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A CACNA1C 16/4885MEN1 2676/4885HTT 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.